Should You Buy Arena Pharmaceuticals, Inc. (ARNA) in Biotechnology Industry?

Tuesday, March 01, 2022 03:29 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Arena Pharmaceuticals, Inc. (ARNA) in Biotechnology Industry?

Arena Pharmaceuticals, Inc. (ARNA) is near the top in its industry group according to InvestorsObserver. ARNA gets an overall rating of 59. That means it scores higher than 59 percent of stocks. Arena Pharmaceuticals, Inc. gets a 90 rank in the Biotechnology industry. Biotechnology is number 103 out of 148 industries.

ARNA has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on ARNA!

See Full ARNA Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 59 means the stock is more attractive than 59 percent of stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock is trading at $94.35 as of 3:28 PM on Tuesday, Mar 1, a drop of -$0.62, or -0.65% from the previous closing price of $94.97. The stock has traded between $94.10 and $95.32 so far today. Volume today is less active than usual. So far 574,501 shares have traded compared to average volume of 1,187,684 shares. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.